Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Nephrology
Volume 2015, Article ID 512549, 3 pages
Case Report

A Case of Nephrotic Syndrome, Showing Evidence of Response to Saquinavir

1Department of Renal Medicine, Canberra Hospital, Garran, ACT 2605, Australia
2Australian National University Medical School, Canberra, Australia
3The Canberra Hospital, Australia

Received 24 September 2014; Revised 6 January 2015; Accepted 11 January 2015

Academic Editor: Patrick Honoré

Copyright © 2015 Giles Walters et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The treatment of primary nephrotic syndrome such as minimal change nephropathy, membranous nephropathy, and focal segmental glomerulosclerosis nephropathy remains challenging. Whilst most cases of idiopathic nephrotic syndrome respond to steroid therapy and experience a limited number of relapses prior to complete remission, some cases suffer from frequent relapses and become steroid dependent or are primarily steroid resistant. Treatment options are limited to immunosuppressive drugs with significant side effect profiles. New modalities targeting novel pathways in the pathogenesis of nephrotic syndrome are actively sought. Here we report the case of a patient with steroid dependent focal segmental glomerulosclerosis (FSGS) nephrotic syndrome with a favourable response to a novel proteasome inhibitor saquinavir.